Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.84 USD | -0.85% | +11.13% | +55.32% |
Apr. 15 | CorMedix's DefenCath Now Commercially Available For US Inpatient Use | MT |
Apr. 15 | CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath®? (Taurolidine and Heparin) | CI |
Financials (USD)
Sales 2024 * | 25.16M | Sales 2025 * | 81.93M | Capitalization | 321M |
---|---|---|---|---|---|
Net income 2024 * | -45M | Net income 2025 * | 6M | EV / Sales 2024 * | 12.8 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 3.92 x |
P/E ratio 2024 * |
-7.92
x | P/E ratio 2025 * |
-59.9
x | Employees | 83 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.99% |
Latest transcript on CorMedix Inc.
1 day | -0.85% | ||
1 week | +11.13% | ||
Current month | +11.13% | ||
1 month | +23.99% | ||
3 months | +98.64% | ||
6 months | +65.44% | ||
Current year | +55.32% |
Managers | Title | Age | Since |
---|---|---|---|
Joseph Todisco
CEO | Chief Executive Officer | 48 | 22-03-17 |
Mathew David
DFI | Director of Finance/CFO | 47 | 20-05-10 |
Tushar Mukherjee
CTO | Chief Tech/Sci/R&D Officer | - | 21-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Myron Kaplan
CHM | Chairman | 79 | 16-04-26 |
Steven Lefkowitz
DFI | Director of Finance/CFO | 68 | 11-08-14 |
Alan Dunton
BRD | Director/Board Member | 70 | 19-02-28 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 0 M€ | +3.53% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-07 | 5.84 | -0.85% | 466,594 |
24-05-06 | 5.89 | +0.86% | 748,677 |
24-05-03 | 5.84 | +8.75% | 1,028,713 |
24-05-02 | 5.37 | -2.72% | 625,572 |
24-05-01 | 5.52 | +5.04% | 902,216 |
Delayed Quote Nasdaq, May 07, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+55.32% | 321M | |
+6.52% | 71.94B | |
+11.16% | 9.27B | |
-11.55% | 5.13B | |
+48.05% | 4.66B | |
+5.09% | 3.97B | |
-14.74% | 2.55B | |
+20.00% | 2.41B | |
-24.89% | 2.36B | |
+21.45% | 2.21B |
- Stock Market
- Equities
- CRMD Stock